Advanced Gene Technologies
Selexis SGE® (Selexis Genetic Elements)
Selexis is the global leader in mammalian cell line development that leverages best-in-class protein expression technologies and modular workflows to create highly specialized solutions that enable the bio-pharmaceutical industry to streamline the drug discovery through development continuum and rapidly commercialize innovative biologic-based medicines and vaccines against diseases of high unmet need such as cancer, autoimmune and inflammatory diseases, infectious diseases, blood, metabolic and genetic disorders as well as dermatology and ophthalmic diseases.
Protein Expression with the SUREtechnology PLATFORM™
Geneva, Switzerland, May 11, 2022 – Selexis SA, a JSR Life Sciences Company, announced today that Great Place to Work®...
Biopharmaceutical companies are increasingly seeking service providers to help them reduce biologics manufacturing...
Our global partners are utilizing Selexis protein expression technologies and proprietary CHO cell line to advance a pipeline of more than 158 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.